Thiard News@F4F

@newsen.bsky.social

3 weeks ago

SciBase Reports Significant Growth in Q4 2025 Amidst Challenges in Market Dynamics SciBase's interim report highlights a 45% increase in net sales for Q4 2025 despite facing operational challenges, marking a critical moment in its growth trajectory.

SciBase Reports Significant Growth in Q4 2025 Amidst Challenges in Market Dynamics #Sweden #Stockholm #dermatology #Nevisense #SciBase

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Nevisense's New EIS Technology Revolutionizes Skin Barrier Impairment Assessment A recent study validates Nevisense's Electrical Impedance Spectroscopy as a crucial tool for evaluating skin barrier health, enhancing traditional assessments.

Nevisense's New EIS Technology Revolutionizes Skin Barrier Impairment Assessment #Sweden #Stockholm #Nevisense #SciBase #EIS

Thiard News@F4F

@newsen.bsky.social

1 month ago

How Nevisense is Transforming Melanoma Detection in the US Clinicians' Practice Discover how US clinicians are leveraging Nevisense to enhance melanoma detection rates and improve diagnostic accuracy through real-world applications.

How Nevisense is Transforming Melanoma Detection in the US Clinicians' Practice #USA #New_York #Nevisense #SciBase #melanoma

Thiard News@F4F

@newsen.bsky.social

1 month ago

SciBase's FDA Approval Allows Expanded Nevisense Usage for Healthcare Professionals SciBase receives FDA approval to extend Nevisense labelling, enabling healthcare practitioners beyond dermatologists to perform crucial skin assessments.

SciBase's FDA Approval Allows Expanded Nevisense Usage for Healthcare Professionals #Sweden #FDA_Approval #Stockholm #Nevisense #SciBase

Thiard News@F4F

@newsen.bsky.social

1 month ago

SciBase’s Nevisense Technology Spearheads Melanoma Detection in NCCN Guidelines SciBase's innovative Nevisense system is now officially recognized in the NCCN guidelines, marking a significant step in melanoma detection and diagnosis.

SciBase’s Nevisense Technology Spearheads Melanoma Detection in NCCN Guidelines #Sweden #Stockholm #Nevisense #SciBase #melanoma

Thiard News@F4F

@newsen.bsky.social

2 months ago

SciBase Holding AB Adjusts Publication Date for 2025 Year-End Report SciBase Holding AB has announced a delay in the publication of its year-end report for 2025, now scheduled for March 13, 2026, to align with a rights issue.

SciBase Holding AB Adjusts Publication Date for 2025 Year-End Report #Sweden #Stockholm #Nevisense #SciBase #financial_report

Thiard News@F4F

@newsen.bsky.social

2 months ago

SciBase Shows Strong Commitment in Ongoing Rights Issue Amidst Shareholder Support SciBase Holding AB is advancing its rights issue, backed by significant commitments from major shareholders, enhancing support for its innovative skin diagnostic solutions.

SciBase Shows Strong Commitment in Ongoing Rights Issue Amidst Shareholder Support #Sweden #Stockholm #Nevisense #SciBase #Life_Science

Thiard News@F4F

@newsen.bsky.social

2 months ago

SciBase Announces Significant Rights Issue to Raise Capital for Future Innovations SciBase Holding AB has published a detailed information document about its ongoing rights issue aimed at raising approximately SEK 83 million. Explore key details about the initiative.

SciBase Announces Significant Rights Issue to Raise Capital for Future Innovations #Sweden #Stockholm #Nevisense #SciBase #Bergh_Securities

Thiard News@F4F

@newsen.bsky.social

3 months ago

SciBase Announces Rights Issue to Raise Approximately 83 Million SEK for US Operations SciBase Holding AB's Board has approved a rights issue of approximately SEK 83 million, focusing on US market expansion. Subscribe from Jan 12-26.

SciBase Announces Rights Issue to Raise Approximately 83 Million SEK for US Operations #Sweden #Stockholm #dermatology #Nevisense #SciBase

Thiard News@F4F

@newsen.bsky.social

4 months ago

SciBase Announces Offer to Repurchase Outstanding Warrants of Series TO 2 SciBase is set to repurchase all outstanding warrants of series TO 2. The offer, which begins December 8, 2025, aims to streamline its financial structure.

SciBase Announces Offer to Repurchase Outstanding Warrants of Series TO 2 #Sweden #Stockholm #Nevisense #SciBase #TO_2_Offer

Thiard News@F4F

@newsen.bsky.social

4 months ago

SciBase Holds Extraordinary General Meeting to Authorize Share Issuance and Enhance Strategic Flexibility SciBase Holding AB recently conducted an extraordinary general meeting, approving a proposal for share issuance and emphasizing strategic growth. This decision positions the company for future advancements in dermatological technology.

SciBase Holds Extraordinary General Meeting to Authorize Share Issuance and Enhance Strategic Flexibility #Sweden #Stockholm #dermatology #Nevisense #SciBase

Thiard News@F4F

@newsen.bsky.social

4 months ago

SciBase Interim Report Shows Growth Amidst Financial Losses in Q3 2025 SciBase's Q3 2025 interim report highlights a 23% increase in net sales, yet reveals financial challenges with rising losses. Insights into their market performance and future plans are discussed.

SciBase Interim Report Shows Growth Amidst Financial Losses in Q3 2025 #Sweden #Stockholm #Nevisense #SciBase #Castle_Biosciences

Thiard News@F4F

@newsen.bsky.social

4 months ago

SciBase and Castle Biosciences Unveil Expanded Collaboration and Loan Agreement SciBase and Castle Biosciences have strengthened their partnership with an expanded collaboration and a SEK 20 million loan agreement to enhance diagnostic solutions.

SciBase and Castle Biosciences Unveil Expanded Collaboration and Loan Agreement #Sweden #Stockholm #Nevisense #SciBase #Castle_Biosciences

Thiard News@F4F

@newsen.bsky.social

6 months ago

SciBase's Nevisense: A Revolutionary Tool in Atopic Dermatitis Skin Barrier Research Discover how SciBase's Nevisense is advancing skin barrier research in atopic dermatitis, enhancing diagnostic methods and treatment monitoring.

SciBase's Nevisense: A Revolutionary Tool in Atopic Dermatitis Skin Barrier Research #Sweden #Stockholm #Atopic_Dermatitis #Nevisense #SciBase

Thiard News@F4F

@newsen.bsky.social

6 months ago

SciBase Partners with Castle Biosciences for Clinical Study in Dermatology Innovations SciBase announces its collaboration with Castle Biosciences, receiving an initial order for a clinical study focused on atopic dermatitis.

SciBase Partners with Castle Biosciences for Clinical Study in Dermatology Innovations #Sweden #Stockholm #Nevisense #SciBase #Castle_Biosciences

Thiard News@F4F

@newsen.bsky.social

7 months ago

New Study Highlights Importance of Reader Studies in Dermatology for Nevisense Validation A recent study confirms the critical role of reader studies in validating SciBase's Nevisense, enhancing real-world diagnostic accuracy in dermatology.

New Study Highlights Importance of Reader Studies in Dermatology for Nevisense Validation #Sweden #Stockholm #Nevisense #SciBase #Reader_Studies

Thiard News@F4F

@newsen.bsky.social

7 months ago

SciBase Reports Significant Growth in Q2 2025 Interim Results Amid Challenges SciBase's Q2 2025 interim report showcases a remarkable 32% increase in net sales, alongside notable advancements in product offerings and collaborations amid ongoing challenges.

SciBase Reports Significant Growth in Q2 2025 Interim Results Amid Challenges #Sweden #Stockholm #dermatology #Nevisense #SciBase

Thiard News@F4F

@newsen.bsky.social

8 months ago

SciBase Finalizes Directed Share Issue to Castle Biosciences - An Investment of SEK 19 Million SciBase Holding AB has concluded a SEK 19 million directed share issue to Castle Biosciences, enhancing its financial position and market strategy.

SciBase Finalizes Directed Share Issue to Castle Biosciences - An Investment of SEK 19 Million #Sweden #Stockholm #Nevisense #SciBase #Castle_Biosciences

Thiard News@F4F

@newsen.bsky.social

8 months ago

SciBase Unveils Exciting Nevisense Pilot Program at Renowned Florida University for Skin Cancer Detection SciBase is launching a significant pilot program for Nevisense's skin cancer detection technology at a top university in Southeast Florida.

SciBase Unveils Exciting Nevisense Pilot Program at Renowned Florida University for Skin Cancer Detection #United_States #Nevisense #SciBase #Skin_Cancer #Southeast_Florida

Thiard News@F4F

@newsen.bsky.social

8 months ago

Palm Beach Dermatology Group Partners with SciBase for Melanoma Detection Innovation SciBase collaborates with Palm Beach Dermatology to enhance melanoma detection with innovative Nevisense technology, aiming to improve patient outcomes.

Palm Beach Dermatology Group Partners with SciBase for Melanoma Detection Innovation #United_States #Palm_Beach #dermatology #Nevisense #SciBase

Thiard News@F4F

@newsen.bsky.social

9 months ago

SciBase Completes Successful Directed Share Issue Raising SEK 11 Million On June 30, 2025, SciBase announced the successful completion of its directed share issue, raising SEK 11 million to expand its operations.

SciBase Completes Successful Directed Share Issue Raising SEK 11 Million #Sweden #Stockholm #Nevisense #SciBase #share_issue

Thiard News@F4F

@newsen.bsky.social

9 months ago

SciBase Announces New Share Issue to Raise Funds for Growth in U.S. Market SciBase Holding AB has approved a directed share issue of SEK 11 million to support market expansion and product development. The funds will facilitate U.S. operations and enhance diagnostic capabilities.

SciBase Announces New Share Issue to Raise Funds for Growth in U.S. Market #Sweden #Stockholm #Nevisense #SciBase #Castle_Biosciences

Thiard News@F4F

@newsen.bsky.social

9 months ago

Highlights from the 2025 Annual General Meeting of SciBase Holding AB The 2025 Annual General Meeting of SciBase Holding AB addressed key financial resolutions and board appointments, showcasing the company's strategic direction.

Highlights from the 2025 Annual General Meeting of SciBase Holding AB #Sweden #Stockholm #Nevisense #SciBase #Annual_General_Meeting

Thiard News@F4F

@newsen.bsky.social

9 months ago

SciBase Secures SEK 19 Million in Directed Share Issue and Plans Additional SEK 11 Million Funding SciBase has confirmed a directed share issue of SEK 19 million and plans for an additional SEK 11 million, enhancing its market position and funding growth.

SciBase Secures SEK 19 Million in Directed Share Issue and Plans Additional SEK 11 Million Funding #Sweden #Stockholm #Nevisense #A.I. #SciBase

Thiard News@F4F

@newsen.bsky.social

9 months ago

SciBase Launches Self-Pay Model in the U.S. to Improve Nevisense Test Accessibility SciBase introduces a Self-Pay Program in the U.S. to enhance access to the Nevisense test for melanoma detection, bypassing insurance restrictions.

SciBase Launches Self-Pay Model in the U.S. to Improve Nevisense Test Accessibility #United_States #Various #Nevisense #SciBase #melanoma

Thiard News@F4F

@newsen.bsky.social

10 months ago

SciBase Takes European Market Leap with Initial Sales Order in Italy SciBase Holding AB embarks on its European expansion journey with a significant sales order in Italy, enhancing melanoma detection and patient care.

SciBase Takes European Market Leap with Initial Sales Order in Italy #Italy #Naples #Nevisense #SciBase #Kilabs

Thiard News@F4F

@newsen.bsky.social

10 months ago

SciBase Celebrates a Milestone of Over 300,000 Patients Tested by Nevisense SciBase's Nevisense technology has been utilized in over 300,000 tests worldwide, offering enhanced melanoma detection and patient care.

SciBase Celebrates a Milestone of Over 300,000 Patients Tested by Nevisense #Sweden #Stockholm #Nevisense #SciBase #melanoma_detection

Thiard News@F4F

@newsen.bsky.social

10 months ago

SciBase Unveils Its Comprehensive Annual Report for 2024 on Website SciBase has published its Annual Report for 2024 online, highlighting achievements and future projections. The report can be accessed for more details.

SciBase Unveils Its Comprehensive Annual Report for 2024 on Website #Sweden #Stockholm #Annual_Report #Nevisense #SciBase

Thiard News@F4F

@newsen.bsky.social

10 months ago

SciBase Reports Remarkable Growth in Q1 2025 Despite Financial Losses In its first quarter report for 2025, SciBase sees significant growth in sales while facing financial challenges. Key insights into their performance are highlighted.

SciBase Reports Remarkable Growth in Q1 2025 Despite Financial Losses #Sweden #Stockholm #dermatology #Nevisense #SciBase

Thiard News@F4F

@newsen.bsky.social

11 months ago

SciBase Unveils Innovative Nevisense V for Enhanced Skin Health Diagnostics SciBase has introduced the next generation Nevisense V, designed to enhance skin cancer diagnostics and improve patient care. Discover its features.

SciBase Unveils Innovative Nevisense V for Enhanced Skin Health Diagnostics #Sweden #Stockholm #dermatology #Nevisense #SciBase